Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Case Report

Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma

Authors: Jennifer Rauw, Shaheeda Ahmed, Teresa Petrella

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

Regional Metastatic Melanoma has a relatively high mortality rate. Adjuvant interferon-alpha (IFN-α) has been shown to improve disease-free survival, post-resection. Cardiotoxicity associated with IFN-α use has been described previously in the literature, but here we describe the first case of pericardial effusion with cardiac tamponade secondary to IFN-α 2b treatment of melanoma. Clinicians should be aware of this potentially lethal complication and the possible acuity of its onset.
Literature
1.
go back to reference Charles MB, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.CrossRef Charles MB, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.CrossRef
2.
go back to reference Slijfer S, et al. Side effects of interferon-a treatment. Pharm World Sci. 2005;27(6):423–31.CrossRef Slijfer S, et al. Side effects of interferon-a treatment. Pharm World Sci. 2005;27(6):423–31.CrossRef
3.
go back to reference Sonnenblick M, Rosin A. Cardiotoxicity of interferon A review of 44 cases. Chest. 1991;99(3):557–61.PubMedCrossRef Sonnenblick M, Rosin A. Cardiotoxicity of interferon A review of 44 cases. Chest. 1991;99(3):557–61.PubMedCrossRef
4.
go back to reference Cohen M, Huberman M, Nesto R. Recombinant alpha 2 interferon- related cardiomyopathy. Am J Med. 1988;85:549–51.PubMedCrossRef Cohen M, Huberman M, Nesto R. Recombinant alpha 2 interferon- related cardiomyopathy. Am J Med. 1988;85:549–51.PubMedCrossRef
5.
go back to reference Zimmerman S, et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother. 1994;9(4):291–9.PubMedCrossRef Zimmerman S, et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother. 1994;9(4):291–9.PubMedCrossRef
6.
go back to reference Kruit WH, et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpected frequent complication. Cancer. 1994;74(10):2850–6.PubMedCrossRef Kruit WH, et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpected frequent complication. Cancer. 1994;74(10):2850–6.PubMedCrossRef
7.
go back to reference Teragawa H, et al. Cardiogenic shock following recombinant alpha-2b interferon therapy for chronic hepatitis C. A case report. Jpn Heart J. 1996;31(1):137–42.CrossRef Teragawa H, et al. Cardiogenic shock following recombinant alpha-2b interferon therapy for chronic hepatitis C. A case report. Jpn Heart J. 1996;31(1):137–42.CrossRef
8.
go back to reference Sikole A, et al. Treatment of hepatitis C in hemodialysis patients with pegulated interferon alpha-2a as monotherapy. Ren Fail. 2007;29:961–1099.PubMedCrossRef Sikole A, et al. Treatment of hepatitis C in hemodialysis patients with pegulated interferon alpha-2a as monotherapy. Ren Fail. 2007;29:961–1099.PubMedCrossRef
9.
go back to reference Boonen A, Stockbrugger RW, van der Linden S. Pericarditis after therapy with interferon-alpha for chronic hepatitis C. Clin Rheumatol. 1999;18:177–9.PubMedCrossRef Boonen A, Stockbrugger RW, van der Linden S. Pericarditis after therapy with interferon-alpha for chronic hepatitis C. Clin Rheumatol. 1999;18:177–9.PubMedCrossRef
10.
go back to reference Nikolaidis LA, et al. Hepatitis C virus-associated pericardial effusion and tamponade in liver transplant recipient. Can J Cardiol. 2004;20(7):719–21.PubMed Nikolaidis LA, et al. Hepatitis C virus-associated pericardial effusion and tamponade in liver transplant recipient. Can J Cardiol. 2004;20(7):719–21.PubMed
11.
go back to reference Vacher-Coponat H, et al. Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with alpha interferon. Nephrol Dial Transplant. 1994;14:2469–71.CrossRef Vacher-Coponat H, et al. Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with alpha interferon. Nephrol Dial Transplant. 1994;14:2469–71.CrossRef
12.
go back to reference Khakoo AY, Halushka MK, Rame JE. Reversible cardiomyopathy caused by administration of interferon α. Nat Clin Prac Cardiovascular Med. 2005;2(1):53–7.CrossRef Khakoo AY, Halushka MK, Rame JE. Reversible cardiomyopathy caused by administration of interferon α. Nat Clin Prac Cardiovascular Med. 2005;2(1):53–7.CrossRef
13.
go back to reference Benjamini O, Kimhi O, Lishner M. Severe pleuropericarditis and cardiomyopathy induced by high dose interferon alpha-2b. IMAJ. 2007;9:486–7.PubMed Benjamini O, Kimhi O, Lishner M. Severe pleuropericarditis and cardiomyopathy induced by high dose interferon alpha-2b. IMAJ. 2007;9:486–7.PubMed
14.
go back to reference Hauschild A, et al. Practical guidelines for the management of interferon-a-2b Side effects in patients receiving adjuvant treatment for melanoma. Cancer. 2008;112(5):982–94.PubMedCrossRef Hauschild A, et al. Practical guidelines for the management of interferon-a-2b Side effects in patients receiving adjuvant treatment for melanoma. Cancer. 2008;112(5):982–94.PubMedCrossRef
15.
16.
go back to reference Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.PubMedCrossRef Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.PubMedCrossRef
Metadata
Title
Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma
Authors
Jennifer Rauw
Shaheeda Ahmed
Teresa Petrella
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9935-7

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.